MOTS-c Side Effects and Safety

Safety & Tolerability

No human safety or clinical trials of MOTS-c have been conducted; all interventional evidence is from animal studies, and the pharmacokinetics of exogenous MOTS-c (bioavailability, distribution, half-life, metabolism) are incompletely characterized. Because MOTS-c has pleiotropic effects across multiple tissues, the full physiological response to supraphysiological dosing is difficult to predict. Human data: MOTS-c was only discovered in 2015. There are no human interventional, safety, or efficacy trials; human evidence is limited to observational and genetic-association studies. Regulatory status: Not approved for human use by any regulatory agency; an early-stage research compound. In mouse models, MOTS-c improved insulin sensitivity and protected against diet-induced obesity via AMPK activation; these are animal findings, not human results. Animal In mouse models, MOTS-c improved insulin sensitivity and protected against diet-induced obesity via AMPK activation; these are animal findings, not human results. Human evidence is limited to observational and genetic-association studies — for example, a mitochondrial MOTS-c variant (K14Q) has been linked to exceptional longevity in human cohorts — which cannot establish safety or causal efficacy. Human observational Human evidence is limited to observational and genetic-association studies — for example, a mitochondrial MOTS-c variant (K14Q) has been linked to exceptional longevity in human cohorts — which cannot establish safety or causal efficacy.